Medtronic announced last week that it has received government approval to evaluate an experimental feature of its insulin pumps called low glucose suspend technology, which stops insulin delivery for two hours when a patient's blood glucose level gets too low. Experts said the technology is an important step toward the development of an artificial pancreas system.

Related Summaries